Blog Post
07/21/2017
By Jonathan A. Havens

Last week, the U.S. House of Representatives (the House) passed by voice vote the FDA Reauthorization Act of 2017 (FDARA or the Act). Introduced on May 16, 2017 by House Energy and Commerce Committee Chairman Greg Walden (R-Ore.), Ranking Member Frank Pallone (D-NJ), and Health Subcommittee Ranking Member Rep. Gene Green (D-TX), the Act would reauthorize four key U.S.

Blog Post
06/05/2017
By Jonathan A. Havens

Recently-confirmed U.S. Food and Drug Administration (FDA or the Agency) Commissioner Dr. Scott Gottlieb indicated in his first remarks to Congress as the Agency’s chief that FDA will be taking steps to lower drug prices. Interestingly, and as Gottlieb admitted in his testimony before a House Appropriations subcommittee, the Agency does not have a direct role in drug pricing. Gottlieb also noted in his statement that that the Trump administration’s federal hiring freeze at FDA is officially over.